Transplant Infectious Disease最新文献

{"title":"Utility of Cytomegalovirus Quantitative Polymerase Chain Reaction in Tissue Biopsy for the Diagnosis of Cytomegalovirus Gastrointestinal Disease Among Solid Organ Transplant Recipients.","authors":"Lucila Baldassarre, Koray Demir, Camille Pelletier Vernooy, Guillaume Butler Laporte, Geneviève Huard, Catherine Girardin, Katarzyna Orlicka, Bich Ngoc Nguyen, Christian Renaud, Charles Poirier, Julie Morisset, Me-Linh Luong","doi":"10.1111/tid.70082","DOIUrl":"https://doi.org/10.1111/tid.70082","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal (GI) cytomegalovirus (CMV) infection is an important cause of morbidity after solid organ transplantation (SOT), and diagnosis mainly relies on histopathology of GI tissue biopsies. CMV detection by quantitative polymerase chain reaction (qPCR) on tissue biopsy is not routinely performed, but potentially holds many practical advantages.</p><p><strong>Methods: </strong>We compared the performance of CMV qPCR on fresh GI biopsies to histopathologic identification for the detection of CMV GI disease.</p><p><strong>Results: </strong>Sixty-one SOT patients with GI symptoms underwent endoscopic assessment, with tissue biopsies obtained. Eleven patients had proven CMV disease by histopathologic detection. Among them, all had a positive qPCR on tissue biopsy (median of 8.7 × 10⁷ IU/mL [interquartile range {IQR} 3.1 × 10⁷, 18.2 × 10⁷]). Of the 49 patients with negative histopathology, 27 (55%) had CMV qPCR-positive tissue biopsy specimens (median of 43 604 IU/mL [IQR 2923, 497 570]). Receiver operating characteristic analysis for optimal threshold value for CMV qPCR on tissue biopsy for diagnosis of proven CMV GI disease was 147 906 IU/mL (sensitivity 100%, specificity 80%, area under the curve = 0.975).</p><p><strong>Conclusion: </strong>Compared to histopathologic detection, CMV qPCR on GI tissue biopsy is highly sensitive for the diagnosis of CMV GI disease in SOT patients, making it a potentially useful adjunctive diagnostic tool for rapid diagnosis in this population.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70082"},"PeriodicalIF":2.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colonization by Vancomycin-Resistant Enterococci in Liver Transplantation: Risk Factors and Survival Impact.","authors":"Nathalia Neves Nunes, Lohayne Alves Ferreira, Fernanda Spadão, Alice Tung Wan Song, Debora Raquel Benedita Terrabuio, Luiz Augusto Carneiro D'Albuquerque, Edson Abdala, Maristela Pinheiro Freire","doi":"10.1111/tid.70072","DOIUrl":"https://doi.org/10.1111/tid.70072","url":null,"abstract":"<p><strong>Background: </strong>Vancomycin-resistant enterococci (VRE) are multidrug-resistant microorganisms (MDRO) commonly isolated in liver transplant recipients and potentially associated with worse outcomes. We aimed to identify risk factors associated with VRE colonization in liver transplantation (LT) and its impact on posttransplant survival.</p><p><strong>Methods: </strong>This is a retrospective cohort that included all adults who underwent LT between 2010 and 2022 at a tertiary-level hospital in São Paulo, Brazil. Multivariate analyses were performed using logistic regression for VRE colonization risk and Cox regression for 180-day survival.</p><p><strong>Results: </strong>A total of 1209 patients were included, 119 patients (9.8%) were colonized with VRE at LT, while 175 (14.5%) were colonized after LT, 77 (6.4%) patients developed VRE infection after LT. In the multivariate analysis, use of SBP prophylaxis, presence of acute-on-chronic liver failure, hepatitis B virus infection, ASA score, length of hospital stay and MELD score were all associated with VRE colonization before LT. For VRE colonization after LT, the predictors were length of hospital stay before LT, MELD score, carbapenem-resistant Gram-negative colonization, intraoperative bleeding and re-transplantation. Note that 180-day mortality rate among VRE colonization and infection was, respectively, 33.6% and 50.6% compared to 17.8% of non-colonized patients, and this difference was not statistically significant after adjustment for confounders in multivariate analysis.</p><p><strong>Conclusion: </strong>VRE colonization or infection had no impact on survival in a large cohort of liver transplantrecipients.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70072"},"PeriodicalIF":2.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Missed Opportunities for HPV Vaccination in Solid Organ Transplant Recipients: Insights From a High-Risk Dermatologic Cohort.","authors":"Alice J Lin, Kevin T Savage, Melissa Pugliano-Mauro","doi":"10.1111/tid.70085","DOIUrl":"https://doi.org/10.1111/tid.70085","url":null,"abstract":"","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70085"},"PeriodicalIF":2.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Unseen Battleground: How Anaerobic Antibiotics Shape GVHD Risk Post-HSCT.","authors":"Ildefonso Espigado, Laura de la Torre Corona","doi":"10.1111/tid.70075","DOIUrl":"https://doi.org/10.1111/tid.70075","url":null,"abstract":"","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70075"},"PeriodicalIF":2.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B Virus Donor Positive to Recipient Negative (D+/R-) Heart and Lung Transplantation: Analysis From the Organ Procurement and Transplantation Network.","authors":"Sara Belga, Robert C Wright, Stephen B Lee, Christine M Durand, Karen Doucette","doi":"10.1111/tid.70054","DOIUrl":"https://doi.org/10.1111/tid.70054","url":null,"abstract":"<p><strong>Introduction: </strong>In nonendemic areas, transplantation from donors with hepatitis B virus (HBV) to recipients without HBV (D+/R-) has been proposed to expand the donor pool; however, data are limited. We aimed to evaluate the epidemiology of HBV in thoracic organ donors, assess HBV-related thoracic organ nonuse, and determine the impact of HBV D+/R- in recipient outcomes.</p><p><strong>Methods: </strong>Adult first-time heart and lung transplant recipients with negative hepatitis B surface antigen (HBsAg) and HBV nucleic acid testing (NAT) were identified through the Organ Procurement and Transplantation Network between January 2004 and December 2022. Multivariable Cox regression models were built to assess the relationship of donor HBV status with death and graft failure.</p><p><strong>Results: </strong>Our final cohort included 64,514 thoracic organ transplant recipients, 53 HBV D+/R- (0.1%) versus 64,461 (99.9%) HBV D-/R-, including 34,547 (53.5%) heart and 29,967 lung (46.5%) transplants. Donors with positive HBsAg or HBV NAT tests represented 0.31% of the donor pool. There were no reported cases of thoracic organ nonuse due to hepatitis, nor were there differences in the rates of HBV-NAT or HBsAg positivity in used versus nonused thoracic organs. In multivariable modeling, HBV D+/R- was not associated with increased hazard of death (adjusted hazard ratio (aHR), 0.80 [95% CI, 0.30-2.13], p = 0.652) or graft failure (aHR, 0.73 [95% CI, 0.27-1.93], p = 0.522) at 1-year.</p><p><strong>Conclusions: </strong>HBV D+/R- thoracic organ transplantation does not appear to have a deleterious impact on recipient or graft survival. However, more data are needed to determine the long-term risk of donor-derived HBV infection and define the optimal management strategies.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70054"},"PeriodicalIF":2.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Repeated Non-Fatal Infections on Quality of Life and Graft Function in ABO-Incompatible Kidney Transplants.","authors":"Federica Bocchi, Isabelle Binet, Dela Golshayan, Fadi Haidar, Cédric Hirzel, Thomas Müller, Thomas Schachtner, Daniel Sidler","doi":"10.1111/tid.70084","DOIUrl":"https://doi.org/10.1111/tid.70084","url":null,"abstract":"<p><strong>Background: </strong>Kidney transplantation (KT) is the preferred treatment for kidney failure, with living donor KT (LDKT) offering better outcomes and improved quality of life (QOL) than deceased donor KT. ABO incompatibility (ABOi) once restricted LDKT, but desensitization protocols now enable ABOi LDKT, expanding the donor pool with favorable outcomes. However, added risks of ABOi remain debated. We examined the impact of repeated infections on graft loss and death in both ABO-compatible (ABOc) and ABOi LDKT recipients.</p><p><strong>Methods: </strong>Retrospective, nationwide Swiss Transplant Cohort Study from May 2008 to December 2022, including all ABOi LDKT patients. Clinically relevant infections (viral, bacterial, fungal, and parasitic) were analyzed as repeated adverse events.</p><p><strong>Results: </strong>Among 227 ABOi LDKT and 1172 ABOc recipients, 13% (183/1399) had ≥ 2 significant infections within the first 6 months. ABOi was independently associated to a higher infection risk (HR 1.21, 95% CI 1.10-1.34, p < 0.001). Patients with early recurrent infections were older, often female, and had ABOi LDKT. Patients with ≥ 2 infections faced increased risks of graft loss, lower eGFR, and reduced QOL.</p><p><strong>Conclusion: </strong>ABOi LDKT patients face a higher risk of recurrent infections, especially within 6 months post-KT, associated with reduced allograft function and lower QOL.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70084"},"PeriodicalIF":2.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144691674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergent Total Gastrectomy for Gas Gangrene of the Stomach due to Clostridium butyricum After Living Donor Liver Transplantation.","authors":"Kenei Furukawa, Tomohiko Taniai, Toru Ikegami","doi":"10.1111/tid.70083","DOIUrl":"https://doi.org/10.1111/tid.70083","url":null,"abstract":"","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70083"},"PeriodicalIF":2.6,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study.","authors":"Estela Giménez, Irene García Cadenas, José Luis Piñana, Eliseo Albert, Lourdes Vázquez, Alejandro Avendaño, Mónica Cabrero, Albert Esquirol, Rodrigo Martino, Javier López-Jiménez, María Ángeles Cuesta, Karem Humala, Sara Villar, Montserrat Rovira, Inmaculada Heras, Teresa Zudaire, Ignacio Arroyo, Amaya Zabalza, Beatriz Aguado, Carlos Solano, David Navarro","doi":"10.1111/tid.70080","DOIUrl":"https://doi.org/10.1111/tid.70080","url":null,"abstract":"<p><strong>Background: </strong>Letermovir (LMV) prophylaxis currently represents the first-line strategy for preventing clinically significant cytomegalovirus (CMV) infection (CsCMVi) in CMV-seropositive recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). A wide variety of CMV DNA thresholds for LMV interruption and preemptive antiviral therapy (PET) inception are in place across transplantation centers.</p><p><strong>Methods: </strong>We evaluated the potential of CMV DNA doubling time (dt) in plasma to distinguish between CsCMVi and abortive CMV infection in allo-HSCT recipients on primary LMV prophylaxis. Data from the Spanish Hematopoietic Transplantation and Cell Therapy Group multicenter registry included 296 allo-HSCT patients receiving LMV prophylaxis. Participating centers used a plasma CMV DNA threshold of ≥1000 IU/mL for initiating PET. The CMV DNA dt was calculated from the first two or three positive polymerase chain reaction (PCR) results based on pre-established criteria.</p><p><strong>Results: </strong>CMV DNAemia developed in 64 recipients (21.6%) with a total of 88 episodes, of which CsCMVi occurred in 9 recipients (3.04%) and included 10 episodes (one patient had confirmed CMV gastrointestinal disease). A non-calculable CMV DNA dt had a negative predictive value of 94% for CsCMVi. For initial episodes with calculable CMV DNA dts (4/7 CsCMVi and 8/57 no-CsCMVi), a threshold of >2.35 days had a specificity of 100% for ruling out CsCMVi.</p><p><strong>Conclusion: </strong>CMV DNA dt could optimize CMV infection management in allo-HSCT patients under LMV prophylaxis, independent of the PCR platform used.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70080"},"PeriodicalIF":2.6,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pure Red Cell Aplasia and C3-Dominant Glomerulonephritis Secondary to Parvovirus B19 in Post Kidney Transplantation Patient: A Case Report.","authors":"Sirihatai Konwai, Supawas Thawornkaew, Chanyanuch Rakpithayanon, Natavudh Townamchai, Jerasit Surintrspanont, Nichthida Tangnuntachai, Noppacharn Uaprasert, Jakapat Vanichanan, Kearkiat Praditpornsilpa, Yingyos Avihingsanon, Suwasin Udomkarnjananun, Thunyatorn Wuttiputhanun","doi":"10.1111/tid.70081","DOIUrl":"https://doi.org/10.1111/tid.70081","url":null,"abstract":"","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70081"},"PeriodicalIF":2.6,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Practice Patterns and Educational Needs of the ESCMID Study Group for Infections in Compromised Hots.","authors":"Maddalena Giannella, Daniele Riccucci, Renato Pascale, Elisa Cordero, Nicolas J Mueller, Monica Slavin, Michael Ison","doi":"10.1111/tid.70076","DOIUrl":"https://doi.org/10.1111/tid.70076","url":null,"abstract":"<p><strong>Background: </strong>The ESCMID Study Group for Infection in Compromised Hosts (ESGICH) conducted a survey to assess its members' demographics, clinical focus, training pathways, research activities, and educational needs. The primary objective was identifying the current expertise and challenges professionals face in immunocompromised host infectious diseases (ICH-ID) and determining how ESGICH can better support their clinical and research endeavors.</p><p><strong>Methods: </strong>A structured questionnaire was distributed to ESGICH members by email and was posted on X to collect information on work settings, patient populations, training, collaborative networks, research involvement, and educational experiences. The survey also assessed interest in future educational initiatives, including certification programs and targeted training opportunities.</p><p><strong>Results: </strong>Overall, 119 colleagues participated in the survey, with the majority being members of ESGICH, which had approximately 230 participants, yielding a response rate of 52%. Most of the respondents were from Europe and noted significant involvement in ICH-ID clinical care and research. Many respondents provide care for transplant recipients and haemato-oncology patients, with varying levels of institutional support, and often had clinical responsibility beyond the ICH-ID population. Training in ICH-ID is inconsistent, with many participants expressing a need for more structured training pathways. Research engagement was high, though support structures varied. Participants identified key educational gaps and expressed interest in webinars, in-person meetings, and certification programs.</p><p><strong>Conclusion: </strong>The findings highlight the need for ESGICH to enhance educational opportunities, strengthen research networks, and advocate for standardized ICH-ID training. Addressing these gaps will improve professional development and ultimately enhance patient care for ICHs.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70076"},"PeriodicalIF":2.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}